OPM Biosciences Snares ￥100M in A New Round of Financing

According to VCBeat, Shanghai OPM Biosciences Co., Ltd. ("OPM Biosciences") has obtained 100 million yuan from China Life Medical Fund in a new round of financing. Haoyue Capital acted as the exclusive financial adviser for this round. Proceeds of this financing will be used to improve the medium production line and CDMO service platform, as well as recruit talents and expand overseas business.

OPM Biosciences has got the strategic investment of nearly 100 million yuan from well-known venture capital funds, including Fortune Capital and Huaxing Capital.

Founded in 2013 and located in Shanghai International Medical Park, OPM Biosciences is a leading provider of serum-free media and the CDMO one-stop service platform.  The company is committed to replacing imported serum-free medium and providing professional CDMO services such as cell line construction, process development and pilot trials.

OPM Biosciences has more than 300 clients, including the domestic first-class biopharmaceutical companies, universities and research institutes. There are more than 30 projects in clinical stage using the media and CDMO service of OPM Biosciences recently. The company's mission is to deliver the most cost-effective media and CDMO services to biotech companies.

During the coronavirus outbreak in China, OPM Biosciences has cooperated with pharmaceutical companies to develop high-quality media in time, produce virus antibodies and vaccines, and provide technical advisory services for many clients developing vaccines.

China Life Medical Fund was established in 2016 by China LifePrivate Equity Investment. It is a leading large-scale medical investment fund in China with an initial scale of 12 billion yuan. The company has invested in a number of enterprises in the field of medical and healthcare, and established a good partnership with many top institutions at home and abroad.

Haoyue Capital is a boutique investment bank focused on China's medical health. Its research and trading areas cover biomedical, innovative medical devices, IVD and precision medicine, medical services and smart medicine.